RACINE, Wis., October 27, 2020 /3BL Media/ – A spatial repellent product designed by SC Johnson could reduce dengue and Zika infections by an estimated 34%, according to new research released by the University of Notre Dame. The data, collected from a Peru-based study, represents the second clinical trial of a five-year global program to investigate the impact of spatial repellents in reducing mosquito-borne disease. The Peru clinical trial was led by the University of Notre Dame in cooperation with the University of California, Davis and U.S. Naval Medical Research Unit Six.
To speed the search to cure diseases, genomics leader HudsonAlpha Institute for Biotechnology generates enormous amounts of DNA data in its research labs. To tackle petabytes of information, they partnered with HPE to design flexible, high-performance systems and connectivity solutions that support intensive research, collaboration, and analysis. The powerful technology is helping HudsonAlpha’s scientists deliver on the tremendous promise of genomics to drive medical breakthroughs including ground-breaking research into Zika and other deadly diseases.
Award underscores company philanthropic commitments and vision
Sanofi Pasteur is proud to announce it is the recipient of The Commonwealth Medical College (TCMC) Wellbeing Award. Frank Epifano, vice president, North America and global finance, commercial operations, accepted the award on October 16 at Mohegan Sun Pocono. Dr. David Greenberg, associate vice president and regional medical head, North America, and Ellyn Schindler, director, North America Corporate Social Responsibility and community engagement, accompanied Epifano.
Join public health panel from GSK, Time, and the Center for Infectious Disease Research and Policy at the University of Minnesota as they discuss the future of tracking emerging diseases
Multimedia with summary
Just a few months after the 2015 outbreak of Ebola was contained, another virus—called Zika—commanded the public stage. It took but 14 months after Zika’s first detection in Brazil for the virus to spread through Latin America and the Caribbean to Florida. So far, the threat has gone unchecked. And to be sure, after Zika, will come another global pathogenic threat—one, that public health experts worry, may do an even better job of outsmarting and overwhelming us. The question is whether technological advances can help us turn the odds.
- Funds will be used for phase II development and manufacturing -
Paris, France, September 28, 2016 /3BL Media/ - Sanofi and its vaccines global business unit Sanofi Pasteur announced today that the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S.
The Johns Hopkins Bloomberg School of Public Health turns 100 this year. The school came to life during a time when women frequently died during childbirth and infant mortality was a grave concern. Inadequate nutrition, sanitation and often-fatal diseases were common.
PARIS, July 12, 2016 /3BL Media/ - Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development of a Zika vaccine candidate. According to the terms of the agreement, WRAIR will transfer its Zika purified inactivated virus (ZPIV) vaccine technology to Sanofi Pasteur, opening the door for a broader collaboration with the U.S. government.
- Building on the company's successful history in developing vaccines against similar viruses, most recently the introduction of Dengvaxia® against dengue, Sanofi Pasteur is launching a Zika vaccine project -
LYON, France, March 10, 2016 /3BL Media/ - Sanofi Pasteur, the vaccines division of Sanofi, announced today that it has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.